What is the price target for PHXM stock?
8 analysts have analysed PHXM and the average price target is 10.17 USD. This implies a price increase of 228.04% is expected in the next year compared to the current price of 3.1.
PHAXIAM Therapeutics SA (PHXM) Forecast, Price Target & Analyst Ratings
NASDAQ:PHXM • US29604W2070
Current stock price
3.1 USD
-0.02 (-0.64%)
At close:
3.1 USD
0 (0%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for PHAXIAM Therapeutics SA (PHXM).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- Mar 20, 2024
- Period
- Q4 / 2023
- EPS Estimate
- -€0.14
- Revenue Estimate
Price Target Details & History
Consensus Price Target and Range
Mean target
$10.17
Upside
+ 228.04%
From current price of $3.10 to mean target of $10.17, Based on 8 analyst forecasts
Low
$8.39
Median
$10.17
High
$12.21
Price Target Revisions
1 Month
-7.80%
3 Months
6.97%
Price Target Summary
8 Wall Street analysts provided a forecast for the next 12 months for PHXM. The average price target is 10.17 USD. This implies a price increase of 228.04% is expected in the next year compared to the current price of 3.1.
The average price target has been revised upward by 6.97% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
85.00%
PHXM was analyzed by 8 analysts. The buy percentage consensus is at 85. So analysts seem to be very confident about PHXM.
In the previous month the buy percentage consensus was at a similar level.
PHXM was analyzed by 8 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- Mar 20, 2024
- Period
- Q4 / 2023
- EPS Estimate
- -€0.14
- Revenue Estimate
- N/A
- Revenue Q2Q
- N/A
- EPS Q2Q
- 86.11%
- Number of Analysts
- 3
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
0.00%
EPS (3 Months)
0.00%
Next Earnings Summary
PHXM is expected to report earnings on 3/20/2024. The consensus EPS estimate for the next earnings is -0.14 USD and the consensus revenue estimate is null USD.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | ||
|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 3.718M -42.45% | 4.18M 12.43% | 6.648M 59.04% | -100.00% | ||||
| EBITDA YoY % growth | -63.841M -14.79% | -51.138M 19.90% | -22.528M 55.95% | -25.806M -14.55% | -19.89M 22.92% | -20.4M -2.56% | N/A | |
| EBIT YoY % growth | -68.832M -14.14% | -56.515M 17.89% | -27.147M 51.96% | -26.418M 2.69% | -20.502M 22.39% | -21.012M -2.49% | -21.322M -1.48% | |
| Operating Margin | -1,851.32% | -1,352.03% | -408.35% | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A -5.11% | N/A 17.43% | N/A 51.41% | -1.62 77.73% | -0.95 41.29% | -0.73 22.94% | N/A |
All data in EUR
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 23 | |
|---|---|
| EPS Q2Q % growth | -0.14 86.11% |
| Revenue Q2Q % growth | N/A |
| EBITDA Q2Q % growth | N/A |
| EBIT Q2Q % growth | N/A |
All data in EUR
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
23.84%
EPS Next 5 Year
N/A
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
-25.99%
Revenue Next 5 Year
-18.92%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
11.18%
EBIT Next 5 Year
N/A
PHAXIAM Therapeutics SA / PHXM Forecast FAQ
Can you provide the upcoming earnings date for PHAXIAM Therapeutics SA?
PHAXIAM Therapeutics SA (PHXM) will report earnings on 2024-03-20, after the market close.
Can you provide the expected long term growth rate for PHAXIAM Therapeutics SA stock?
The expected long term growth rate for PHAXIAM Therapeutics SA (PHXM) is -25.99%.